November 23, 2022 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – September 2022 Read more
November 23, 2022 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari – september 2022 Read more
October 26, 2022 Non Regulatory InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2023 Annual General Meeting Read more
October 26, 2022 Non Regulatory InDex Pharmaceuticals Holding AB (publ) offentliggör valberedning inför årsstämman 2023 Read more
October 5, 2022 Non Regulatory InDex Pharmaceuticals to exhibit at United European Gastroenterology Week Read more
October 5, 2022 Non Regulatory InDex Pharmaceuticals deltar som utställare på United European Gastroenterology Week Read more
August 26, 2022 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – June 2022 Read more
August 26, 2022 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari – juni 2022 Read more
August 16, 2022 Non Regulatory InDex Pharmaceuticals announces successful interactions with the PMDA for the clinical development of cobitolimod in Japan Read more
August 16, 2022 Non Regulatory InDex Pharmaceuticals meddelar framgångsrika interaktioner med PMDA för den kliniska utvecklingen av cobitolimod i Japan Read more
July 13, 2022 Regulatory InDex Pharmaceuticals gets new patent for cobitolimod granted in Europe Read more
July 13, 2022 Regulatory InDex Pharmaceuticals får nytt patent för cobitolimod beviljat i Europa Read more
June 1, 2022 Regulatory Bulletin from the Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
May 16, 2022 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – March 2022 Read more
May 16, 2022 Regulatory InDex Pharmaceuticals Holding AB (publ) delårsrapport för januari – mars 2022 Read more
May 12, 2022 Non Regulatory InDex Pharmaceuticals deltar som utställare på Digestive Disease Week Read more
May 2, 2022 Regulatory InDex Pharmaceuticals strengthens the organization with Eva Arlander as Chief Development Officer and announces changes in the composition of the management team Read more
May 2, 2022 Regulatory InDex Pharmaceuticals stärker organisationen med Eva Arlander som Chief Development Officer samt presenterar förändringar i ledningsgruppens sammansättning Read more
April 28, 2022 Regulatory Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
April 8, 2022 Regulatory InDex Pharmaceuticals Holding AB (publ) offentliggör årsredovisning för 2021 Read more
April 8, 2022 Regulatory InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2021 Read more
March 13, 2022 Regulatory InDex Pharmaceuticals prepares for commercialisation of cobitolimod Read more
March 13, 2022 Regulatory InDex Pharmaceuticals prepares for commercialisation of cobitolimod Read more
March 13, 2022 Regulatory InDex Pharmaceuticals förbereder kommersialisering av cobitolimod Read more
March 7, 2022 Non Regulatory Reminder: InDex Pharmaceuticals hosts Capital Markets Day on March 14, 2022 Read more
March 7, 2022 Non Regulatory Påminnelse: InDex Pharmaceuticals arrangerar kapitalmarknadsdag den 14 mars 2022 Read more
February 23, 2022 Regulatory InDex Pharmaceuticals Holding AB (publ) bokslutskommuniké 2021 Read more
February 15, 2022 Non Regulatory Invitation to InDex Pharmaceuticals’ Capital Markets Day on March 14, 2022 Read more
February 15, 2022 Non Regulatory Inbjudan till InDex Pharmaceuticals kapitalmarknadsdag den 14 mars 2022 Read more
February 13, 2022 Regulatory COO Pernilla Sandwall is leaving InDex Pharmaceuticals for a CEO position Read more
February 13, 2022 Regulatory COO Pernilla Sandwall lämnar InDex Pharmaceuticals för en VD-roll Read more